MNG908
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.419
- DNA_REPAIR+0.304
- PEROXISOME+0.273
- PANCREAS_BETA_CELLS+0.236
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.199
- FATTY_ACID_METABOLISM+0.191
- BILE_ACID_METABOLISM+0.189
- XENOBIOTIC_METABOLISM+0.182
- P53_PATHWAY+0.171
- ADIPOGENESIS+0.147
Top 10 suppressed
- G2M_CHECKPOINT-0.503
- MITOTIC_SPINDLE-0.500
- WNT_BETA_CATENIN_SIGNALING-0.464
- TNFA_SIGNALING_VIA_NFKB-0.366
- ANGIOGENESIS-0.353
- E2F_TARGETS-0.350
- IL6_JAK_STAT3_SIGNALING-0.347
- NOTCH_SIGNALING-0.344
- INFLAMMATORY_RESPONSE-0.342
- UV_RESPONSE_DN-0.307
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-E2-A572-01A-13R-A31O-07 | — | B | 0.889 |
| 2 | TCGA-49-4486-01A-01R-1206-07 | — | cohortA2 | 0.851 |
| 3 | 20140057.LumB | — | B | 0.843 |
| 4 | MDT-AP-2103 | Med | Medulloblastoma | 0.841 |
| 5 | SRR4296114 | — | cohortA1 | 0.833 |
| 6 | TCGA-AQ-A54O-01A-11R-A266-07 | — | B | 0.824 |
| 7 | TCGA-LL-A6FQ-01A-11R-A31O-07 | — | B | 0.821 |
| 8 | TCGA-OR-A5L3-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.821 |
| 9 | TCGA-GU-A763-01A-11R-A32O-07 | — | — | 0.817 |
| 10 | TCGA-AC-A3YJ-01A-11R-A22U-07 | — | B | 0.814 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.419 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.304 | Idelalisib | — uncovered |
| PEROXISOME | 0.273 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.236 | Cobimetinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.199 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.191 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.189 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.182 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.171 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.147 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.110 | Idelalisib | — uncovered |
| MYOGENESIS | 0.107 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.096 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.094 | Temsirolimus | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.076 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.071 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.062 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.001 | Remibrutinib | — uncovered |